Literature DB >> 3229942

Changes in drug sensitivity of a human astrocytoma clone previously treated with 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea in vitro.

S C Barranco1, C M Townsend, V K Jenkins, S K Koester, B Y Ho, K J Reumont.   

Abstract

We have shown in earlier studies that repeated weekly exposures of a human astrocytoma clone (AST 3-4) to MeCCNU (10 micrograms/ml for 1 h per week) produced a linear decrease in survival over the first 3 weekly treatments. But, after that time these cells became progressively more resistant to the 10 micrograms/ml concentration of the agent. In the studies reported here we show that these previously treated cells were also less responsive to other doses ranging from 1 to 30 micrograms MeCCNU/ml. This change in sensitivity to MeCCNU was accompanied by collateral changes in response to other agents: resistance to BCNU and Galactitol, increased sensitivity to Adriamycin, and no change to ionizing radiation. These experiments suggest that once repeated treatments with a single agent cause a tumor cell population to become more resistant, sensitivity to other agents may also change unpredictably.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3229942     DOI: 10.1007/bf00173647

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  15 in total

1.  A novel cell-to-cell interaction between mast cells and other cell types.

Authors:  G Greenberg; G Burnstock
Journal:  Exp Cell Res       Date:  1983-08       Impact factor: 3.905

2.  Determination of ploidy and proliferative characteristics of human solid tumors by pulse cytophotometry.

Authors:  B Barlogie; W Göhde; D A Johnston; L Smallwood; J Schumann; B Drewinko; E J Freireich
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

3.  Interactions between tumor subpopulations affecting their sensitivity to the antineoplastic agents cyclophosphamide and methotrexate.

Authors:  B E Miller; F R Miller; G H Heppner
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

4.  Serum-dependent "cannibalism" and autodestruction in cultures of human small cell carcinoma of the lung.

Authors:  M Brouwer; L de Ley; C A Feltkamp; J Elema; A P Jongsma
Journal:  Cancer Res       Date:  1984-07       Impact factor: 12.701

5.  Clonal interaction in tumours.

Authors:  M F Woodruff; J D Ansell; G M Forbes; J C Gordon; D I Burton; H S Micklem
Journal:  Nature       Date:  1982-10-28       Impact factor: 49.962

Review 6.  Patterns of resistance and therapeutic synergism among alkylating agents.

Authors:  F M Schabel; M W Trader; W R Laster; G P Wheeler; M H Witt
Journal:  Antibiot Chemother (1971)       Date:  1978

7.  Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.

Authors:  B A Teicher; C A Cucchi; J B Lee; J L Flatow; A Rosowsky; E Frei
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

8.  Cultured mouse marrow cell lines: interactions between fibroblastoid cells and monocytes.

Authors:  D Zipori; A Friedman; M Tamir; D Silverberg; Z Malik
Journal:  J Cell Physiol       Date:  1984-02       Impact factor: 6.384

9.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines.

Authors:  N Kartner; J R Riordan; V Ling
Journal:  Science       Date:  1983-09-23       Impact factor: 47.728

10.  Effect of cell-cell interactions on drug sensitivity and growth of drug-sensitive and -resistant tumor cells in spheroids.

Authors:  P J Tofilon; N Buckley; D F Deen
Journal:  Science       Date:  1984-11-16       Impact factor: 47.728

View more
  2 in total

1.  Relationship between glutathione levels and drug or radiation sensitivities in human gastric cancer cell lines in vitro.

Authors:  S C Barranco; B Weintraub; K K MacLean; E G Beasley; V K Jenkins; C M Townsend
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

2.  Gracilaria edulis extract induces apoptosis and inhibits tumor in Ehrlich ascites tumor cells in vivo.

Authors:  Satyajit Patra; Meenakshi Sundaram Muthuraman
Journal:  BMC Complement Altern Med       Date:  2013-11-25       Impact factor: 3.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.